Skip to Content
  • Pfizer Says They Won’t Break Up

    Pfizer has been mulling over the idea of turning into at least two Pfizers for a long time now, but they’re out with an announcement this morning that th… Read More
  • Label the Label Labels

    Here’s a (by now) little-known bit of pharma history, specifically for the companies that had sites in New Jersey. Back around 1990-91, the state passed a… Read More
  • Valeant Sure Picks the Winners

    You may remember brodulamab, the anti-IL-17-receptor antibody (update: fixed a mistake in the mechanism) that was under development by Amgen and AstraZeneca for… Read More
  • Expertology

    I’ve been thinking about “right to try” laws, the ones that are trying to open up access to not-yet-approved drugs for patients who wish to ta… Read More
  • AstraZeneca’s Nasty Surprise

    Something got severely screwed up here. That’s the only conclusion I can draw after seeing AstraZeneca get a Complete Response Letter (CRL) from the FDA f… Read More
  • Sarepta’s Day at the FDA

    I last wrote about Sarepta and eteplirsen, their proposed therapy for Duchenne muscular dystrophy, here. They’re in front of an FDA advisory committee to… Read More
Page 4 of 24« First...23456...1020...Last »